-
Research on Collaborative Innovation Development of Biomedicine Industry in Guangdong-Hong Kong-Macao Greater Bay Area
Time of Update: 2021-03-22
The Guangdong-Hong Kong-Macao Greater Bay Area is an important area where my country’s biomedical industry gathers. It has a complete industrial foundation and leading strength. With the developmen
-
Huawei vice president appointed as CEO of Yunnan Baiyao
Time of Update: 2021-03-22
The chief executive officer (president) of the company shall serve from the date of review and approval of the board of directors to the expiration of the ninth board of directors.
-
National physician license electronic acceleration! Claim rate of more than 90%
Time of Update: 2021-03-22
In September 2019, the Medical Administration and Hospital Administration of the Health Commission issued the "Notice on Further Strengthening the Verification and Management of Electronic Registration Information of Medical Institutions, Physicians, and Nurses".
-
Domestic heavy-weight new drugs have been approved, innovative drug product selection is the key!
Time of Update: 2021-03-22
Taltazep is the first domestically produced Chinese drug for the treatment of systemic lupus erythematosus that has been approved for marketing in China in more than 60 years.
-
Hengrui Medicine Carrelizumab and Famitinib clinical trials approved by FDA
Time of Update: 2021-03-22
Up to now, the accumulated research and development expenses of carrelizumab for injection related projects are approximately RMB 1.
After inquiries, famitinib malate currently has sorafenib, sunitinib, pezopanib and other similar products approved for marketing at home and abroad.
-
Major clinical progress of global new tumor drugs | February 2021
Time of Update: 2021-03-22
CheckMate-274, a phase 3 trial of nivolumab adjuvant treatment of high-risk muscular invasive urothelial carcinoma, reached the primary clinical endpointOn February 8, BMS announced the results of the Phase III CheckMate-274 study, Opdivo (nivolumab) adjuvant treatment of patients with high recurrence risk of muscular invasive urothelial carcinoma after surgery, in all random populations and PD-L1 The primary study endpoint was reached in patients with expression ≥1%, which can significantly improve the disease-free survival (DFS) of patients.
-
Important speech at the two sessions!
Time of Update: 2021-03-22
Xi Jinping emphasized that at the critical moment of the fight against the new crown pneumonia epidemic, the majority of medical workers have lived up to the trust of the party and the people.
-
The country is about to start special insulin procurement! The second batch of centralized procurement of medicines in six provinces and two districts is about to start
Time of Update: 2021-03-22
According to the news received late at night last night, Nanjing’s main topics are four:The country will carry out special procurement with quantities, and the first batch of test water varieties will be insulin.
-
Top 10 most innovative pharmaceutical companies: Pfizer, AZ, GSK...
Time of Update: 2021-03-22
From the biotech companies behind the first mRNA vaccines (Pfizer BioNTech and Moderna) to real estate developers providing high-quality affordable housing (Stablegold Hospitality), the world’s 50 most innovative companies are committed to solving COVID-19 transformation Society.
-
2021 National Primary Health Assembly convenes to announce 6 key tasks
Time of Update: 2021-03-22
It is mentioned in the provincial-level communication materials of this meeting that Guangdong Province guides the medical community to innovate the internal personnel and salary distribution system, establish an incentive mechanism for benefit sharing, share development results, and share profit increments; Superimposed on the policy of “first-class financial supply, second-class performance management” for grassroots medical and health institutions, grassroots medical staff get reasonable remuneration by relying on high-quality services and more work.
-
Shaanxi Provincial Food and Drug Administration issued 332 standards for traditional Chinese medicine formula granules
Time of Update: 2021-03-22
Source: Shaanxi Provincial Drug AdministrationOn March 9, the Shaanxi Provincial Drug Administration issued an announcement on the "Shaanxi Provincial Standards for Traditional Chinese Medicine Formula Granules" (Volumes 1 and 2), and this standard shall come into force on the date of issuance.
-
20 billion false invoices were investigated for involvement in pharmaceutical companies
Time of Update: 2021-03-22
The criminal suspects opened more than 1,600 shell companies, and without real goods transactions, they issued a large number of false invoices for waste materials, coal, medicine and other industries, and the amount of false invoices was as high as 20 billion yuan.
-
Key words of the Report on the Work of the Government: promoting innovation, expanding collection, health care reform, and platform anti-monopoly
Time of Update: 2021-03-22
Use market mechanism to encourage enterprise innovation Strengthen the dominant position of enterprise innovation, encourage leading companies to form innovative consortia, expand channels for integration of industry, university, research and use, improve the property rights incentive mechanism for scientific and technological achievements, improve the regulatory system and development policy of venture capital, and promote mass entrepreneurship innovation in depth.
-
From Zebtini", we can see the road of globalization of China's innovative drugs
Time of Update: 2021-03-22
However, it needs to be clearly recognized that if you want to participate in the global competition in the development of innovative drugs, especially in mature markets such as the United States, Europe, and Japan, Chinese companies still have a comparative advantage in terms of operating income and R&D investment.
-
Huadong Medicine MB-102 injection clinical trial application was accepted
Time of Update: 2021-03-22
On March 9th, Huadong Medicine issued an announcement stating that its wholly-owned subsidiary Sino-American Huadong received the "Notice of Acceptance" approved and issued by NMPA, and the applicatio
-
National Medical Insurance Administration, the latest development of medical insurance payment reform
Time of Update: 2021-03-22
As early as May 2019, the National Medical Insurance Administration announced a list of 30 DRG-paying national pilot cities, and then released 376 ADRG groups and 618 DRG sub-groups in October 2019 and June 2020, respectively, to further promote DRG Payment reform.
-
To Biao Qilu!
Time of Update: 2021-03-22
Source: official website of the State Food and Drug Administration, Mi Nei. com database Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
-
The story of Coley's Toxins
Time of Update: 2021-03-22
Unfortunately, this therapy failed to pass GMP production standards and modern clinical trials in time and was listed as an unproven therapy by the FDA in 1963.
Later, chemotherapy and radiotherapy with clearer mechanisms and more controllable production entered tumor treatment successively, and this toxin therapy began to be squeezed out.
-
The state announced a 40% increase in the salary of the health center staff in this place
Time of Update: 2021-03-22
Performance reform of township hospitals, medical staff salaries increased by more than 40% The case shows that Hanyin County has promoted the reform of the salary system, fully implemented the "two permits", and established the township health center's incentive mechanism for the "Public Welfare Type One Guarantee, and Public Welfare Type Two Management".
-
1 billion injections! Qi Lu and Haisco have just passed the review and Yuandong is here
Time of Update: 2021-03-22
0 Chinese Drug Evaluation DatabaseThere are 15 manufacturers of Palonosetron Hydrochloride Injection including Qilu Pharmaceutical (Hainan), Zhengda Tianqing Pharmaceutical Group, Yangtze River Sichuan Hairong Pharmaceutical, Jiangsu Hengrui Pharmaceutical, among which Qilu Pharmaceutical (Hainan) and Liaoning Haisco The two pharmaceutical companies have been approved for supplementary applications.
